13 research outputs found
Bayesian joint estimation of non-Gaussianity and the power spectrum
We propose a rigorous, non-perturbative, Bayesian framework which enables one
jointly to test Gaussianity and estimate the power spectrum of CMB
anisotropies. It makes use of the Hilbert space of an harmonic oscillator to
set up an exact likelihood function, dependent on the power spectrum and on a
set of parameters , which are zero for Gaussian processes. The latter
can be expressed as series of cumulants; indeed they perturbatively reduce to
cumulants. However they have the advantage that their variation is essentially
unconstrained. Any truncation(i.e.: finite set of ) therefore still
produces a proper distribution - something which cannot be said of the only
other such tool on offer, the Edgeworth expansion. We apply our method to Very
Small Array (VSA) simulations based on signal Gaussianity, showing that our
algorithm is indeed not biased.Comment: 11pages, 4 figures, submitted to MNRA
Re-visiting Meltsner: Policy Advice Systems and the Multi-Dimensional Nature of Professional Policy Analysis
10.2139/ssrn.15462511-2
Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes
Angiopoietin-like 4 (ANGPTL4) is an endogenous inhibitor of lipoprotein lipase that modulates lipid levels, coronary atherosclerosis risk, and nutrient partitioning. We hypothesize that loss of ANGPTL4 function might improve glucose homeostasis and decrease risk of type 2 diabetes (T2D). We investigate protein-altering variants in ANGPTL4 among 58,124 participants in the DiscovEHR human genetics study, with follow-up studies in 82,766 T2D cases and 498,761 controls. Carriers of p.E40K, a variant that abolishes ANGPTL4 ability to inhibit lipoprotein lipase, have lower odds of T2D (odds ratio 0.89, 95% confidence interval 0.85-0.92, p = 6.3 x 10(-10)), lower fasting glucose, and greater insulin sensitivity. Predicted loss-of-function variants are associated with lower odds of T2D among 32,015 cases and 84,006 controls (odds ratio 0.71, 95% confidence interval 0.49-0.99, p = 0.041). Functional studies in Angptl4-deficient mice confirm improved insulin sensitivity and glucose homeostasis. In conclusion, genetic inactivation of ANGPTL4 is associated with improved glucose homeostasis and reduced risk of T2D.Peer reviewe